Table 2.

Adoptive transfer of Salmonella-CFA/I-induced CD25⁺CD4⁺ T cells enhances Foxp3⁺ frequency in the recipient mice^a.

	Treatment ^b	% Fox3⁺/CD4^{+ c}	Average Clinical Score ^d
PBS	IgG1	8.2 ± 2.4	4.2 ± 0.5
	α-TGF-β	6.2 ± 3.6	4.4 ± 0.6
H696	CD25⁺/IgG1	37.2 ± 3.6 ^{*, †, +}	0.4 ± 0.2 ^{*, †, +}
	CD25⁺/α-TGF-β	12.2 ± 3.2	4.0 ± 0.5
	CD25⁻/IgG1	16.5 ± 3.1 ^**	2.4 ± 0.8 ^{**, ††}
	CD25⁻/α-TGF-β	11.4 ± 2.8	4.2 ± 0.5
H647	CD25⁺/IgG1	14.5 ± 2.7 ^††	3.8 ± 0.6
	CD25⁺/α-TGF-β	8.54 ± 2.2	4.4 ± 0.8
	CD25⁻/IgG1	11.8 ± 2.5	3.8 ± 0.2
	CD25⁻/α-TGF-β	10.3 ± 3.8	4.2 ± 0.6

Naïve SJL recipients were adoptively transferred with cell-sorted CD25⁺CD4⁺ and CD25⁻CD4⁺ T cells from mice previously (2 wks earlier) immunized with H696 or H647 vaccines one day prior to EAE.

Mice were treated twice with anti-TGF-β mAb or its isotype IgG1 control Ab on the same day of adoptive transfer and 4 days post-EAE challenge.

At the peak of EAE, CD4⁺ T cells were purified from HNLNs obtained from individual mice and measured Foxp3⁺ frequency by FACS. Seven mice/group were used and data represent mean ± SEM. ^*, p < 0.001; ^**, p < 0.05 versus PBS/IgG1; ^†, p < 0.001; ^††, p < 0.05 versus CD25⁺/α-TGF-β; ⁺, p < 0.001 versus CD25⁻/IgG1.

Upon termination of experiment, clinical scores were measured, and the data represent mean clinical score ± SEM. ^*, p < 0.001; ^**, p < 0.05 versus PBS/IgG1; ^†, p < 0.001; ^††, p < 0.05 versus CD25⁺/α-TGF-β; ⁺, p < 0.001 versus CD25⁻/IgG1.